Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251840 | 0.79 | HSD11B1 (0.50) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL133056 | 0.77 | HSD11B1 (0.48) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL19557166 | 0.77 | HSD11B1 (0.48) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL12714 | 0.77 | HSD11B1 (0.48) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL19557168 | 0.77 | HSD11B1 (0.48) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| Ammonia Solution, Strong SCHEMBL11787415 | 0.77 | HSD11B1 (0.48) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL23780828 | 0.76 | HSD11B1 (0.56) | ALDH1A1HSD11B1KDM4EMEN1KMT2A | |
| SCHEMBL5487136 | 0.74 | HSD11B1 (0.46) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL2672258 | 0.74 | HSD11B1 (0.46) | HTTALDH1A1CRHBPCRHR2MCOLN3 | |
| SCHEMBL4389277 | 0.74 | HSD11B1 (0.46) | HTTALDH1A1CRHBPCRHR2MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | claimed |
| EP-3728214-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2020-10-28 | — | — | EP | claimed |
| CN-111727185-A | Substituted N-heterocyclyl-and N-heteroaryltetrahydropyrimidines and their salts and their use as herbicidal active substances | 拜耳公司 | 2020-09-29 | — | — | CN | claimed |
| EP-2697206-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2019-04-03 | — | — | EP | claimed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | claimed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | claimed |
| US-20130131091-A1 | HARMFUL ORGANISM CONTROL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2013-05-23 | — | — | US | claimed |
| EP-2578084-A1 | NOXIOUS ORGANISM CONTROL AGENT | Meiji Seika Pharma Co., Ltd. (JP) | 2013-04-10 | — | — | EP | claimed |
| EP-0693285-B1 | Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss | LILLY CO ELI (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0653427-B1 | Galanthamine derivatives, a process for their preparation and their use as medicaments | AVENTIS PHARMA INC (US) | 2002-01-23 | — | — | EP | claimed |
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | BLACK LARRY J (US) | 2001-12-13 | — | — | US | claimed |
| US-6323195-B1 | ENZYME INHIBITORS AND COGNITION ACTIVATORS | AVENTIS PHARMACEUTICALS INC. | 2001-11-27 | — | — | US | claimed |
| CN-1315955-A | Novel carbapenem derivatives | MEIJI SEIKA KAISHA (JP) | 2001-10-03 | — | — | CN | claimed |
| EP-0635264-B1 | Antiestrogenic 2-phenyl-3-aroylbenzothiophenes as hypoglycemic agents | LILLY CO ELI (US) | 1997-09-10 | — | — | EP | claimed |
| EP-0693285-A2 | Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0653427-A1 | Galanthamine derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0635264-A2 | Antiestrogens as hypoglycemic agents | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | claimed |
| US-4218457-A | ANTICANCER ACTIVITY AND IMMUNOSTIMULATING ACTIVITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-08-19 | — | — | US | claimed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | DDT, NOTUM, AGPS | HTT 706/4885ALDH1A1 201/4885CRHBP 3584/4885 |
| US-20130131091-A1 | HARMFUL ORGANISM CONTROL AGENT | PRXL2A, O60361, H1-10 | HTT 162/4885ALDH1A1 1827/4885CRHBP 2150/4885 |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | HTT 3775/4885ALDH1A1 24/4885CRHBP 1770/4885 |
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | SOST, BMP2, PTH1R | HTT 2654/4885ALDH1A1 1610/4885CRHBP 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.